Patents by Inventor Sue J. SOHN

Sue J. SOHN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TIGIT and CD112R blockade
    Patent number: 11919953
    Abstract: Provided herein are TIGIT binding proteins, CD112R binding proteins, and combinations thereof. Also provided are compositions comprising TIGIT binding proteins and CD112R binding proteins, optionally further comprising PD-1 binding proteins. Related conjugates, fusion proteins, nucleic acids, vectors, host cells and kits are additionally provided. Further provided are pharmaceutical compositions comprising a TIGIT binding protein, CD112R binding protein, or a combination thereof, optionally, further comprising a PD-1 antigen binding protein, or a conjugate, fusion protein, nucleic acid, vector, or host cell, and a pharmaceutically acceptable carrier, diluent, or excipient, and methods of treating subjects in need thereof.
    Type: Grant
    Filed: July 14, 2021
    Date of Patent: March 5, 2024
    Assignee: AMGEN INC.
    Inventors: Sue J. Sohn, Marissa Mock, Ian Nevin Foltz, Agnieszka Kielczewska, Kathy Manchulenko, Yannick Bulliard, Xiaoshan Min
  • INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS
    Publication number: 20220289807
    Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc fusion molecules that preferentially expand and activate cells and are amenable to large scale production. Also provided herein are methods of making and using the compositions of the present invention.
    Type: Application
    Filed: August 13, 2020
    Publication date: September 15, 2022
    Applicant: AMGEN INC.
    Inventors: Darren L. BATES, Sue J. SOHN, Hannah Beth CATTERALL, Zhulun WANG
  • TIGIT AND CD112R BLOCKADE
    Publication number: 20220017616
    Abstract: Provided herein are TIGIT binding proteins, CD112R binding proteins, and combinations thereof. Also provided are compositions comprising TIGIT binding proteins and CD112R binding proteins, optionally further comprising PD-1 binding proteins. Related conjugates, fusion proteins, nucleic acids, vectors, host cells and kits are additionally provided. Further provided are pharmaceutical compositions comprising a TIGIT binding protein, CD112R binding protein, or a combination thereof, optionally, further comprising a PD-1 antigen binding protein, or a conjugate, fusion protein, nucleic acid, vector, or host cell, and a pharmaceutically acceptable carrier, diluent, or excipient, and methods of treating subjects in need thereof.
    Type: Application
    Filed: July 14, 2021
    Publication date: January 20, 2022
    Inventors: Sue J. SOHN, Marissa MOCK, Ian Nevin FOLTZ, Agnieszka KIELCZEWSKA, Kathy MANCHULENKO, Yannick BULLIARD, Xiaoshan MIN